Jennison Associates
XENE icon

Jennison Associates’s Xenon Pharmaceuticals XENE Stock Holding History

Jennison Associates’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Sell
208,060
-1,110,754
-84% -$61.7M 0.01% 375
2026
Q1 		$76.7M Buy
1,318,814
+26,759
+2% +$1.23M 0.05% 166
2025
Q4 		$57.9M Buy
1,292,055
+156,820
+14% +$6.59M 0.03% 192
2025
Q3 		$45.6M Buy
1,135,235
+438,852
+63% +$15.5M 0.03% 228
2025
Q2 		$21.8M Sell
696,383
-80,310
-10% -$2.62M 0.01% 325
2025
Q1 		$26.1M Sell
776,693
-24,860
-3% -$944K 0.02% 302
2024
Q4 		$31.4M Buy
801,553
+224,892
+39% +$9.3M 0.02% 291
2024
Q3 		$22.7M Buy
576,661
+6,389
+1% +$258K 0.01% 328
2024
Q2 		$22.2M Buy
570,272
+6,320
+1% +$253K 0.01% 317
2024
Q1 		$24.3M Sell
563,952
-2,444
-0.4% -$112K 0.02% 324
2023
Q4 		$26.1M Buy
566,396
+352,573
+165% +$12.5M 0.02% 299
2023
Q3 		$7.3M Buy
213,823
+25,432
+13% +$951K 0.01% 391
2023
Q2 		$7.25M Buy
+188,391
New +$7.49M 0.01% 400

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Jennison Associates's XENE Position: Q2 2026 in Review

Jennison Associates reduced its Xenon Pharmaceuticals (XENE) stake by 84% in Q2 2026, selling an estimated $61.7M and leaving 208,060 shares worth $12.6M. The position accounts for 0.01% of the portfolio, ranked #375.

Jennison Associates first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. The position peaked at $76.7M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Jennison Associates held 208,060 shares of Xenon Pharmaceuticals worth $12.6M as of Q2 2026.
  • Jennison Associates sold 1,110,754 Xenon Pharmaceuticals shares in Q2 2026, an estimated $61.7M.
  • Xenon Pharmaceuticals made up 0.01% of Jennison Associates's portfolio in Q2 2026, its #375 holding.
  • Jennison Associates first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Jennison Associates's Xenon Pharmaceuticals position peaked at $76.7M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.